Conference on biopharma opportunities to be held on 25-26 February

The ChemTECH BioPharma World.IE Conference themed 'Bio-Pharmaceuticals: A Next Big Opportunity' is all set to be held on February 25 and 26, 2020. The Knowledge Partner for the event is BIORx Venture Advisors. 

New Delhi: Biopharmaceuticals are among the most sophisticated and elegant achievements of modern science. Radically new concepts are making it to the market,  offer even more amazing promises of regenerative medicine or disease remission. Yet there are operational and technological challenges. Reproducing large molecules reliably at an industrial scale requires manufacturing capabilities of a previously unknown sophistication. This sophistication comes at a great cost.
The opportunity in biopharmaceuticals is big and growing too rapidly to ignore. Today, biopharmaceuticals generate global revenues of USD 163 billion, making up about 20 percent of the pharma market. It’s by far the fastest-growing part of the industry: biopharma’s current annual growth rate of more than 8 percent is double that of conventional pharma, and growth is expected to continue at that rate for the foreseeable future. Biopharmaceuticals have set new standards for blockbuster drugs as well.
The ChemTECH BioPharma World.IE Conference to be held on February 25 and 26, 2020 will explore and address the opportunity and the challenges in the area of ‘Bio-Pharmaceuticals: A Next Big Opportunity.’ The Knowledge Partner for the event is BIORx Venture Advisors.
Chaired by Dr Dinesh Dua, Chairman, Pharmexcil, and Executive Director, Nectar Lifesciences Limited the conference will cover the Nuances of  Bio-Pharmaceuticals  –  the 360-degree approach to address the move from the scientific frontier to the business mainstream; while the Digital  Transformation session will reassess many of the strategies,  technologies,  and operational approaches;  Supply  Chain  &  Logistics  –  which is enabling the operational and technological challenges.
Welcoming the members of the advisory board, he said, “This exposition and conference comes absolutely and appropriately in time to: one, make sure we invite the Indian participants and researchers to show that now is the time that we move up the value chain and two, why not innovation?  Innovation in  Biologics is right there. The amount of collaboration that is happening between academia and the industry as compared to  10 years is absolutely tremendous. In such a situation, it’s an honor and a pleasure to be heading this excellent committee. This might well mark a revolution in the biopharmaceutical space. I expect India to be a major force to reckon with in biosimilar space”
Over the years,  ChemTECH has organized the  BioPharma  World  Expo with exceptional expertise with a vision of providing a platform for pharmaceutical machinery and equipment for sourcing new business and getting the latest market insight. When times change so must we, thus, owing to the ongoing pandemic, the BioPharma World Expo and Conference 2021 will be conducted entirely on a digital platform that will connect industry influencers from the Biopharma, Biotechnology and Life Science.
The conference will also focus on the Bio Start-ups through the Accelerating Bio-Innovations to Marketplace session. The idea is to sculpt the future of Bio-innovation in India. Chaired by Dr Uday Saxena, Co-Founder, Reagene Biosciences the session will showcase entrepreneurs and innovators producing new research that are driving the next wave of innovation and start-up ecosystem.
To drive the agenda of the conference and to fulfill its potential to garner attention to the field of Biopharmaceuticals and to successfully navigate the promises and challenges of this segment, ChemTECH has partnered with BIORx Venture Advisors Private Limited.
As the Knowledge Partner to the conference, Mr. Vishal Gandhi, Founder & CEO said, “BIORx is very excited to partner for the second time with this forum to deepen our commitment to promote the  Biopharmaceuticals emerging opportunity globally.  We not only see big corporates making a strong commitment for R&D but Startups are equally excited about the much-needed relief of targeted molecular therapies and this platform will involve 360* view and hopefully position  India as a  BioPharma hub on the world map given its strengths in Pharmaceuticals and Biotechnology”.
As biopharma moves from the scientific frontier to the business mainstream, the industry will increasingly be forced to confront the same challenges faced by other businesses: maintaining competitiveness by ensuring affordability, quality, and delivery performance.